An argument 23andSerge can't win...23andme but not medicine
Posted Nov 14 2009 10:01pm
" As I had postulated before, in order tomove towards a profitable directionthe DTC companies would have to choose "Medically Relevant" or "Novelty Testing" From this recent email sent to me by a reader it is clear, 23andME is Choosing to become a clinical service, without accepting the clinical responsibility."
The first "A Novelty Test" which will be solely for ancestry. 23andMe Ancestry Edition – $399 The second "A health test" which will be solely for medicine while still disclaiming it is not.23andMe Health Edition – $429
"With the launch of the 23andMe Health Edition we are releasing 13 new carrier status reports. These reports will help you know more about what may be in store for the next generation. We are expanding our cystic fibrosis panel report to cover the full panel of mutations recommended by the American College of Medical Genetics, as well as several additional mutations. We will also be providing data for most of the mutations routinely screened for in the Ashkenazi Jewish population, including those associated with Tay-Sachs disease, Canavan disease and Bloom’s syndrome.
We are also continuing to expand our drug response offerings. The next report to come out, Pseudocholinesterase Deficiency, contains information for anyone who will be undergoing surgery."